Browse EMP2

Summary
SymbolEMP2
Nameepithelial membrane protein 2
Aliases XMP; Protein XMP; EMP-2
Chromosomal Location16p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus membrane Multi-pass membrane protein Cell membrane Apical cell membrane Membrane raft Cytoplasm Nucleus Note=Localizes in cytoplasm, foot processes and cell bodies of podocytes and nucleus of endothelial cells of kidney. Localizes to the apical cell surface in the luminal epithelium and glandular epithelium. Colocalized with ITGB1 and GPI-anchor proteins on plasma membrane.
Domain PF00822 PMP-22/EMP/MP20/Claudin family
Function

Functions as a key regulator of cell membrane composition by regulating proteins surface expression. Also, plays a role in regulation of processes including cell migration, cell proliferation, cell contraction and cell adhesion. Negatively regulates caveolae formation by reducing CAV1 expression and CAV1 amount by increasing lysosomal degradation (PubMed:24814193). Facilitates surface trafficking and formation of lipid rafts bearing GPI-anchor proteins (By similarity). Regulates surface expression of MHC1 and ICAM1 proteins increasing susceptibility to T-cell mediated cytotoxicity (By similarity). Regulates the plasma membrane expression of the integrin heterodimers ITGA6-ITGB1, ITGA5-ITGB3 and ITGA5-ITGB1 resulting in modulation of cell-matrix adhesion (PubMed:16216233). Also regulates many processes through PTK2. Regulates blood vessel endothelial cell migration and angiogenesis by regulating VEGF protein expression through PTK2 activation (PubMed:23439602). Regulates cell migration and cell contraction through PTK2 and SRC activation (PubMed:21637765, PubMed:22728127). Regulates focal adhesion density, F-actin conformation and cell adhesion capacity through interaction with PTK2 (PubMed:19494199). Positively regulates cell proliferation (PubMed:24814193). Plays a role during cell death and cell blebbing (PubMed:12107182). Promotes angiogenesis and vasculogenesis through induction of VEGFA via a HIF1A-dependent pathway (PubMed:23334331). Also plays a role in embryo implantation by regulating surface trafficking of integrin heterodimer ITGA5-ITGB3 (PubMed:16487956). May play a role in glomerular filtration (By similarity).

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001570 vasculogenesis
GO:0001667 ameboidal-type cell migration
GO:0001765 membrane raft assembly
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001913 T cell mediated cytotoxicity
GO:0001952 regulation of cell-matrix adhesion
GO:0001954 positive regulation of cell-matrix adhesion
GO:0001977 renal system process involved in regulation of blood volume
GO:0002250 adaptive immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0003013 circulatory system process
GO:0003014 renal system process
GO:0003071 renal system process involved in regulation of systemic arterial blood pressure
GO:0003073 regulation of systemic arterial blood pressure
GO:0003093 regulation of glomerular filtration
GO:0003094 glomerular filtration
GO:0007009 plasma membrane organization
GO:0007015 actin filament organization
GO:0007034 vacuolar transport
GO:0007160 cell-matrix adhesion
GO:0007229 integrin-mediated signaling pathway
GO:0007565 female pregnancy
GO:0007566 embryo implantation
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0010594 regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0016197 endosomal transport
GO:0016482 cytosolic transport
GO:0030031 cell projection assembly
GO:0030048 actin filament-based movement
GO:0031579 membrane raft organization
GO:0031589 cell-substrate adhesion
GO:0032060 bleb assembly
GO:0032147 activation of protein kinase activity
GO:0033674 positive regulation of kinase activity
GO:0034394 protein localization to cell surface
GO:0043534 blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0044057 regulation of system process
GO:0044091 membrane biogenesis
GO:0044706 multi-multicellular organism process
GO:0045022 early endosome to late endosome transport
GO:0045765 regulation of angiogenesis
GO:0045785 positive regulation of cell adhesion
GO:0045860 positive regulation of protein kinase activity
GO:0048514 blood vessel morphogenesis
GO:0050878 regulation of body fluid levels
GO:0070252 actin-mediated cell contraction
GO:0071709 membrane assembly
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0097205 renal filtration
GO:0098801 regulation of renal system process
GO:0098927 vesicle-mediated transport between endosomal compartments
GO:1901342 regulation of vasculature development
GO:1990778 protein localization to cell periphery
GO:2001044 regulation of integrin-mediated signaling pathway
GO:2001046 positive regulation of integrin-mediated signaling pathway
GO:2001212 regulation of vasculogenesis
Molecular Function GO:0005178 integrin binding
GO:0050839 cell adhesion molecule binding
Cellular Component GO:0016324 apical plasma membrane
GO:0045121 membrane raft
GO:0045177 apical part of cell
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolEMP2
Nameepithelial membrane protein 2
Aliases XMP; Protein XMP; EMP-2
Chromosomal Location16p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EMP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between EMP2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24644285GlioblastomaInhibit immunityEpithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma. EMP2 had low or undetectable expression in normal brain but was highly expressed in GBM as 95% of patients showed some expression of the protein. As a proof of principle to determine whether EMP2 could serve as a target for therapy, cells were treated using specific anti-EMP2 antibody reagents.
20670949Ovarian CarcinomaInhibit immunityEMP2 was found to be highly expressed in >70% of serous and endometrioid ovarian tumors compared with nonmalignant ovarian epithelium using a human ovarian cancer tissue microarray. Treatment of human ovarian cancer cell lines with anti-EMP2 diabodies induced cell death and retarded cell growth, and these response rates correlated with cellular EMP2 expression.
Summary
SymbolEMP2
Nameepithelial membrane protein 2
Aliases XMP; Protein XMP; EMP-2
Chromosomal Location16p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EMP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEMP2
Nameepithelial membrane protein 2
Aliases XMP; Protein XMP; EMP-2
Chromosomal Location16p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EMP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2720.574
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9770.581
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2380.866
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.130.695
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1140.949
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1480.945
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1680.714
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.270.864
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0560.974
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0220.988
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2970.887
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2160.104
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolEMP2
Nameepithelial membrane protein 2
Aliases XMP; Protein XMP; EMP-2
Chromosomal Location16p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EMP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEMP2
Nameepithelial membrane protein 2
Aliases XMP; Protein XMP; EMP-2
Chromosomal Location16p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EMP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EMP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEMP2
Nameepithelial membrane protein 2
Aliases XMP; Protein XMP; EMP-2
Chromosomal Location16p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EMP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEMP2
Nameepithelial membrane protein 2
Aliases XMP; Protein XMP; EMP-2
Chromosomal Location16p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EMP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEMP2
Nameepithelial membrane protein 2
Aliases XMP; Protein XMP; EMP-2
Chromosomal Location16p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EMP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEMP2
Nameepithelial membrane protein 2
Aliases XMP; Protein XMP; EMP-2
Chromosomal Location16p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EMP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.